Seclidemstat mesylate
Based on 11 publication(s) in Google Scholar
Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.80%
- CAS No.: 2044953-70-8
- Formule: C21H27ClN4O7S2
- Masse moléculaire:547.04
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Seclidemstat mesylate
More- Mol Cancer. 2025 Apr 23;24(1):122. [Abstract]
- Nat Cell Biol. 2022 Mar;24(3):373-383. [Abstract]
- Cancer Lett. 2024 Aug 21:600:217182. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- Mol Divers. 2024 Dec;28(6):4403-4424. [Abstract]
- ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. [Abstract]
- Biochem Biophys Res Commun. 2025 Jan 27:750:151330. [Abstract]
- Boston University. 2025.
- Indiana University. 2025.
- bioRxiv. 2024 October 29.
- bioRxiv. 2020 May.
Activité biologique
|
KDM1/LSD1 |
Seclidemstat (72 hours) mesylate inhibits SWI/SNF-mutation-dependent tumor cell proliferation with IC50 ranging from 0.013 to 2.819 μM (COV434, BIN67, SCCOHT-1, TOV21G, SKOV3, A427, H522, A549, H1299, G401, G402, HCC15 cells)[2].
Seclidemstat (72 hours) mesylate promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in SCCOHT cell lines (SCCOHT-1, BIN67, and COV434 cells)[2].
Seclidemstat (3 μM) mesylate promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2044953-70-8
-
Appearance Solid
-
Masse moléculaire 547.04
-
Formule C21H27ClN4O7S2
-
Color Off-white to light yellow
-
SMILES
O=C(N/N=C(C1=CC(Cl)=CC=C1O)\C)C2=CC=CC(S(=O)(N3CCN(C)CC3)=O)=C2.CS(O)(=O)=O
-
Synonyms
SP-2577 mesylate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer. [Abstract]2025 Apr 23;24(1):122. PMID: 40264166 -
Nat Cell Biol
YAP/TAZ drives cell proliferation and tumour growth via a polyamine-eIF5A hypusination-LSD1 axis. [Abstract]2022 Mar;24(3):373-383. PMID: 35177822 -
Cancer Lett
Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer. [Abstract]2024 Aug 21:600:217182. PMID: 39154703 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
Mol Divers
Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors. [Abstract]2024 Dec;28(6):4403-4424. PMID: 38522046 -
ACS Pharmacol Transl Sci
Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology. [Abstract]2021 Nov 12;4(6):1818-1834. PMID: 34927013 -
Biochem Biophys Res Commun
Histone lysine demethylase 1A inhibitors, seclidemstat and tranylcypromine, induce astrocytogenesis in rat neural stem cells. [Abstract]2025 Jan 27:750:151330. PMID: 39899938 -
-
-
-
Solvant et solubilité
DMSO : 53.33 mg/mL (97.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Dai XJ, et al. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [published correction appears in J Med Chem. 2021 May 13;64(9):6410-6411]. J Med Chem. 2021;64(5):2466-2488. [Content Brief]
[2]. Soldi R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One. 2020;15(7):e0235705. Published 2020 Jul 10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8280 mL | 9.1401 mL | 18.2802 mL | 45.7005 mL |
| 5 mM | 0.3656 mL | 1.8280 mL | 3.6560 mL | 9.1401 mL | |
| 10 mM | 0.1828 mL | 0.9140 mL | 1.8280 mL | 4.5700 mL | |
| 15 mM | 0.1219 mL | 0.6093 mL | 1.2187 mL | 3.0467 mL | |
| 20 mM | 0.0914 mL | 0.4570 mL | 0.9140 mL | 2.2850 mL | |
| 25 mM | 0.0731 mL | 0.3656 mL | 0.7312 mL | 1.8280 mL | |
| 30 mM | 0.0609 mL | 0.3047 mL | 0.6093 mL | 1.5233 mL | |
| 40 mM | 0.0457 mL | 0.2285 mL | 0.4570 mL | 1.1425 mL | |
| 50 mM | 0.0366 mL | 0.1828 mL | 0.3656 mL | 0.9140 mL | |
| 60 mM | 0.0305 mL | 0.1523 mL | 0.3047 mL | 0.7617 mL | |
| 80 mM | 0.0229 mL | 0.1143 mL | 0.2285 mL | 0.5713 mL |
Seclidemstat mesylate Related Classifications
HY-103713A Related Classifications
Powered by Bioz